Avantor® Reports Third Quarter 2026 Results
Avantor, Inc. (AVTR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Avantor® Reports Third Quarter 2026 Results • Net sales of $1,698.3 million; increase of 4.6%; organic increase of 5.2% • Diluted GAAP EPS of $0.30; adjusted EPS of $0.22 • Raised FY 2026 organic revenue growth, adjusted EPS and free cash flow guidance RADNOR, Pa. –
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The earnings beat and updated guidance provide fresh data that can influence short‑term trading decisions.
Market read
The new earnings and guidance data are material for AVTR and may affect related sector stocks.
What to watch
Potential headwinds from foreign‑currency translation and higher SG&A could temper earnings momentum.
Avantor® Reports Third Quarter 2026 Results
Third-quarter net sales increased 4.6% and organic net sales increased 5.2%, both segments posted organic growth, and fiscal 2026 organic revenue growth, adjusted EPS and free cash flow guidance were raised. Adjusted EBITDA, adjusted operating income, adjusted net income and free cash flow were below their prior-year-period amounts, while VWR Distribution & Services adjusted operating income margin declined.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net sales, three months ended September 30, 2026GAAP | $1.70B | – | 4.6% |
| Organic net sales growth, three months ended September 30, 2026non-GAAP | 5.2% | – | 5.2% |
| Foreign currency translation impact on net sales, three months ended September 30, 2026other | negative impact of 0.6% | – | – |
| Cost of sales, three months ended September 30, 2026GAAP | $1.16B | – | – |
| Gross profit, three months ended September 30, 2026GAAP | $534.8M | – | – |
| Selling, general and administrative expenses, three months ended September 30, 2026GAAP | $395.3M | – | – |
| Operating income, three months ended September 30, 2026GAAP | $139.5M | – | – |
| Operating income margin, three months ended September 30, 2026GAAP | 8.2% | – | – |
| Adjusted Operating Income, three months ended September 30, 2026non-GAAP | $227.6M | – | – |
| Adjusted Operating Income margin, three months ended September 30, 2026non-GAAP | 13.4% | – | – |
| Interest expense, net, three months ended September 30, 2026GAAP | −$39.9M | – | – |
| Loss on extinguishment of debt, three months ended September 30, 2026GAAP | −$800K | – | – |
| Other expense, net, three months ended September 30, 2026GAAP | −$800K | – | – |
| Income before income taxes, three months ended September 30, 2026GAAP | $98M | – | – |
| Income tax benefit, three months ended September 30, 2026GAAP | $105.4M | – | – |
| Net income, three months ended September 30, 2026GAAP | $203.4M | – | – |
| Net income margin, three months ended September 30, 2026GAAP | 12.0% | – | – |
| Adjusted net income, three months ended September 30, 2026non-GAAP | $146.4M | – | – |
| Diluted earnings per share, three months ended September 30, 2026GAAP | $0.30 | – | – |
| Basic earnings per share, three months ended September 30, 2026GAAP | $0.30 | – | – |
| Adjusted EPS, three months ended September 30, 2026non-GAAP | $0.22 | – | – |
| Adjusted EBITDA, three months ended September 30, 2026non-GAAP | $256.9M | – | – |
| Adjusted EBITDA margin, three months ended September 30, 2026non-GAAP | 15.1% | – | – |
| Weighted average diluted shares outstanding, three months ended September 30, 2026GAAP | 680.9M | – | – |
| Net sales, nine months ended September 30, 2026GAAP | $4.97B | – | 1.7% |
| Organic net sales growth, nine months ended September 30, 2026non-GAAP | 0.3% | – | 0.3% |
| Gross profit, nine months ended September 30, 2026GAAP | $1.57B | – | – |
| Operating income, nine months ended September 30, 2026GAAP | $360.8M | – | – |
| Net income, nine months ended September 30, 2026GAAP | $284.8M | – | – |
| Diluted earnings per share, nine months ended September 30, 2026GAAP | $0.42 | – | – |
| Adjusted EPS, nine months ended September 30, 2026non-GAAP | $0.60 | – | – |
| Adjusted EBITDA, nine months ended September 30, 2026non-GAAP | $730.6M | – | – |
| Adjusted EBITDA margin, nine months ended September 30, 2026non-GAAP | 14.7% | – | – |
| Adjusted Operating Income, nine months ended September 30, 2026non-GAAP | $643.3M | – | – |
| Adjusted Operating Income margin, nine months ended September 30, 2026non-GAAP | 12.9% | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| VWR Distribution & Services, three months ended September 30, 2026Foreign currency translation had a negative impact of 0.8%, resulting in a sales increase of 5.8% on an organic basis. Adjusted Operating Income margin declined versus the prior year due to unfavorable product mix and higher SG&A expenses, partially offset by higher sales volume. | $1.23B | – | 5.0% |
| Bioscience & Medtech Products, three months ended September 30, 2026Foreign currency translation had a negative impact of 0.1%, resulting in a 3.6% sales increase on an organic basis. Adjusted Operating Income margin was flat versus the prior year due to higher sales volume and commercial excellence, partially offset by higher SG&A expenses. | $464.5M | – | 3.5% |
| VWR Distribution & Services, nine months ended September 30, 2026Foreign currency impact was 1.6% and organic net sales growth was 0.9%. | $3.62B | – | 2.5% |
| Bioscience & Medtech Products, nine months ended September 30, 2026Foreign currency impact was 1.1% and organic net sales growth was (1.4)%. | $1.35B | – | (0.3)% |
Fiscal 2026 guidance (as of October 28, 2026) outlook
- Revenue+0.75% to +1.25% organic revenue growth
- Tax rateAdjusted effective tax rate between 22.0% and 22.5%
- NoteAdjusted EBITDA margin: 14.8% to 15.3%
- NoteAdjusted EPS: $0.81 to $0.83
- NoteFree cash flow: $525M to $550M
- NoteReported revenue growth range is +1.5% to +2.0%, reflecting +0.75% foreign exchange tailwind
- NoteBlended EUR/USD exchange rate of 1.15
- NoteNet interest expense is expected to decline modestly when compared to Fiscal 2025
- NoteFully diluted share count of 679M shares
- NoteFree cash flow excludes cash restructuring costs
Capital returns
- Shares repurchased to satisfy employee tax obligations for vested stock-based awards were $(1.1) million for the three months ended September 30, 2026.
- Shares repurchased to satisfy employee tax obligations for vested stock-based awards were $(5.0) million for the nine months ended September 30, 2026.
What drove it
- Total third-quarter net sales increased 4.6%, while foreign currency translation had a negative impact of 0.6%, resulting in 5.2% organic net sales growth.
- VWR Distribution & Services delivered 5.8% organic sales growth.
- Bioscience & Medtech Products returned to organic growth, reporting 3.6% organic sales growth.
- Management cited improving execution and stronger end markets as a foundation for sustained revenue growth.
- Higher sales volume partially offset unfavorable product mix and higher SG&A expenses in VWR Distribution & Services.
- Higher sales volume and commercial excellence offset higher SG&A expenses in Bioscience & Medtech Products.
Concerns
- Adjusted EBITDA was $256.9 million, compared with $267.9 million in the prior-year period, and adjusted EBITDA margin was 15.1%, compared with 16.5%.
- Adjusted Operating Income was $227.6 million, compared with $237.3 million in the prior-year period, and adjusted Operating Income margin was 13.4%, compared with 14.6%.
- Adjusted net income was $146.4 million, compared with $151.1 million in the prior-year period.
- VWR Distribution & Services adjusted Operating Income was $119.4 million, compared with $132.0 million, while its margin was 9.7%, compared with 11.2%.
- Third-quarter operating cash flow was $195.1 million and free cash flow was $156.2 million, below $207.4 million and $171.7 million, respectively, in the prior-year period.
- GAAP net leverage was 9.6x as of September 30, 2026.
What to watch
- Delivery against updated fiscal 2026 organic revenue growth guidance of +0.75% to +1.25%.
- Delivery against fiscal 2026 adjusted EBITDA margin guidance of 14.8% to 15.3%.
- VWR Distribution & Services product mix, SG&A expenses and adjusted Operating Income margin.
- Bioscience & Medtech Products' continuation of organic sales growth and commercial excellence.
- Free cash flow delivery against updated fiscal 2026 guidance of $525M to $550M.
- Progress in adjusted net leverage, which was 3.1x as of September 30, 2026.
Balance sheet and cash flow
- Cash and cash equivalents were $464.3 million as of September 30, 2026, compared with $365.4 million as of December 31, 2025.
- Total debt, gross, was $3,699.7 million as of September 30, 2026.
- GAAP net leverage was 9.6x and adjusted net leverage was 3.1x as of September 30, 2026.
- Net cash provided by operating activities was $195.1 million for the three months ended September 30, 2026, compared with $207.4 million in the prior-year period.
- Free cash flow was $156.2 million for the three months ended September 30, 2026, compared with $171.7 million in the prior-year period.
- Capital expenditures were $(38.9) million for the three months ended September 30, 2026, compared with $(35.7) million in the prior-year period.
- Net cash provided by operating activities was $432.0 million for the nine months ended September 30, 2026, compared with $471.1 million in the prior-year period.
- Free cash flow was $324.2 million for the nine months ended September 30, 2026, compared with $379.2 million in the prior-year period.
- Capital expenditures were $(110.0) million for the nine months ended September 30, 2026, compared with $(93.3) million in the prior-year period.
Analysis
Avantor returned to reported and organic sales growth in the third quarter. Net sales were $1,698.3 million, up 4.6%, and organic net sales growth was 5.2% after a negative 0.6% foreign currency translation impact. VWR Distribution & Services posted $1,233.8 million of sales and 5.8% organic growth, while Bioscience & Medtech Products reported $464.5 million of sales and 3.6% organic growth. For the nine months ended September 30, 2026, net sales were $4,972.0 million, up 1.7%, while organic net sales growth was 0.3%.
Reported profitability improved sharply from the prior-year quarter, which included a $785.0 million non-cash goodwill impairment charge related to the former Distribution reporting unit. Third-quarter operating income was $139.5 million versus an operating loss of $(648.8) million, and net income was $203.4 million versus a net loss of $(711.8) million. The quarter also included a $105.4 million income tax benefit. Diluted GAAP EPS was $0.30, compared with $(1.04), while adjusted EPS was unchanged at $0.22.
Underlying profitability was lower year over year. Adjusted EBITDA was $256.9 million, with a 15.1% margin, compared with $267.9 million and 16.5%. Adjusted Operating Income was $227.6 million and its margin was 13.4%, compared with $237.3 million and 14.6%. VWR Distribution & Services adjusted Operating Income margin was 9.7%, down from 11.2%, due to unfavorable product mix and higher SG&A expenses, partially offset by higher sales volume. Bioscience & Medtech Products adjusted Operating Income margin was flat at 26.6%, as higher sales volume and commercial excellence were offset by higher SG&A expenses.
Cash generation remained positive but was lower than the prior-year period. Operating cash flow was $195.1 million and free cash flow was $156.2 million, compared with $207.4 million and $171.7 million, respectively. Total debt, gross, was $3,699.7 million and cash and cash equivalents were $464.3 million as of September 30, 2026. GAAP net leverage was 9.6x and adjusted net leverage was 3.1x.
Management raised fiscal 2026 organic revenue growth guidance to +0.75% to +1.25% from -0.5% to +0.5%, adjusted EPS guidance to $0.81 to $0.83 from $0.80 to $0.83, and free cash flow guidance to $525M to $550M from $500M to $550M. The adjusted EBITDA margin range remains 14.8% to 15.3%. The updated outlook calls for reported revenue growth of +1.5% to +2.0%, reflecting a +0.75% foreign exchange tailwind.
Management, verbatim
We are delighted to return to year-over-year growth in the third quarter. We are not done with our Revival journey yet, but this achievement reflects the dedication of our associates and the progress we are making to sharpen our strategic focus and improve execution. Third quarter results exceeded our expectations across revenue and adjusted EPS, and we generated robust free cash flow that allowed us to further strengthen our balance sheet.
Emmanuel Ligner, President and Chief Executive Officer
VWR Distribution & Services delivered another quarter of improving revenue performance, with organic growth accelerating to 5.8%, and Bioscience & Medtech Products returned to organic growth as expected. We believe that improving execution and stronger end markets provide a foundation for sustained revenue growth, and we remain focused on execution to build on our positive momentum.
Emmanuel Ligner, President and Chief Executive Officer
Not in the filing
stated, not guessed- GAAP gross margin for the three months ended September 30, 2026 and 2025 was not printed.
- GAAP gross margin for the nine months ended September 30, 2026 and 2025 was not printed.
- Prior-quarter comparisons for reported metrics were not provided.
- Actual effective tax rate was not provided.
- Fiscal 2026 gross margin guidance was not provided.
- Fiscal 2026 operating expenses guidance was not provided.
- Cash dividend information was not provided.
- The previous outlook covered the full year 2026 only, so there is no guidance for this third quarter to compare against.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Avantor is a leading provider of life‑science and advanced‑technology products, reporting its quarterly performance via an SEC Form 8‑K.
Ticker impact
Avantor reported Q3 2026 results and issued updated FY 2026 guidance, including raised organic revenue growth and free cash flow targets.
likely upward pressure as investors price in the updated guidance
The earnings beat and the upward‑adjusted guidance provide fresh, material information that can move the stock in the short term.
Market effects
Life‑science tools sector may see broader optimism from Avantor's results.
U.S. markets may see a modest lift in related biotech and specialty chemicals stocks.
Limited to investors tracking global life‑science supply chains.
Counterpoint
If the guidance uplift is modest, the market may have already priced it in, limiting upside.
Key entities
- companyAvantor, Inc.
Issuer of the earnings release and guidance update.



